CompletedNot applicableNCT00709280
Infant Study of Inhaled Saline in Cystic Fibrosis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CF Therapeutics Development Network Coordinating Center
- Principal Investigator
- Stephanie Davis, MDUniversity of North Carolina, Chapel Hill
- Intervention
- 7% Hypertonic Saline (HS)(drug)
- Enrollment
- 321 enrolled
- Eligibility
- All sexes
- Timeline
- 2009 – 2011
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Stanford University / Lucile S. Packard Children's Hospital, Palo Alto, California, United States
- The Children's Hospital, Aurora, Colorado, United States
- Children's Memorial Hospital and Northwestern University, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- University of Louisville, Louisville, Kentucky, United States
- Johns Hopkins University / Johns Hopkins Hospital, Baltimore, Maryland, United States
- University of Michigan / C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
- Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
- Cardinal Glennon Children's Hospital, St Louis, Missouri, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- University of Nebraska, Omaha, Nebraska, United States
- Women and Children's Hospital of Buffalo, Buffalo, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Cystic Fibrosis Foundation · National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00709280 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS